Inhibikase Therapeutics (IKT) Stock Chart & Stock Price History $1.85 -0.13 (-6.53%) As of 04/4/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Inhibikase Therapeutics Stock Price Performance 5 Day Performance-15.98%1 Month Performance-17.49%3 Month Performance-44.58%6 Month Performance+46.03%Year-To-Date Performance-43.38%1 Year Performance-16.36% Receive IKT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address IKT Stock Chart for Saturday, April, 5, 2025 IKT Chart by TradingViewRemove Ads Inhibikase Therapeutics Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization04/04/2025$1.98$1.84-7.07%$1.93$1.77139,629 shs$136.79 million04/03/2025$2.18$1.98-9.17%$2.12$1.92104,880 shs$137.34 million04/02/2025$2.09$2.18+4.31%$2.27$2.00140,910 shs$151.21 million04/01/2025$2.19$2.09-4.57%$2.23$2.03236,268 shs$144.97 million03/31/2025$2.29$2.19-4.37%$2.33$2.14162,184 shs$151.90 million03/28/2025$2.37$2.29-3.38%$2.39$2.20104,788 shs$158.84 million03/27/2025$2.39$2.37-0.84%$2.42$2.33134,147 shs$164.39 million03/26/2025$2.37$2.39+0.84%$2.46$2.29155,765 shs$165.78 million03/25/2025$2.37$2.37$2.40$2.29136,911 shs$164.39 million03/24/2025$2.37$2.37$2.44$2.3374,955 shs$164.39 million Get the Latest News and Ratings for IKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 03/21/2025$2.42$2.37-2.07%$2.46$2.36112,818 shs$164.39 million03/20/2025$2.47$2.42-2.02%$2.58$2.35109,201 shs$167.86 million03/19/2025$2.37$2.47+4.22%$2.56$2.34171,743 shs$171.32 million03/18/2025$2.36$2.37+0.42%$2.43$2.27155,512 shs$164.39 million03/17/2025$2.25$2.36+4.89%$2.40$2.24175,997 shs$163.69 million03/14/2025$2.20$2.25+2.27%$2.26$2.1371,825 shs$156.06 million03/13/2025$2.23$2.20-1.35%$2.26$2.08109,884 shs$152.60 million03/12/2025$2.20$2.23+1.36%$2.26$2.1272,456 shs$154.68 million03/11/2025$1.99$2.20+10.55%$2.21$1.9491,072 shs$152.60 million03/10/2025$1.96$1.99+1.53%$2.22$1.91155,073 shs$138.03 million03/07/2025$2.11$1.96-7.11%$2.15$1.93184,914 shs$135.95 million03/06/2025$2.23$2.11-5.38%$2.29$2.09102,113 shs$146.35 million03/05/2025$2.20$2.23+1.36%$2.50$2.17117,710 shs$154.68 million03/04/2025$2.27$2.20-3.08%$2.23$2.07179,751 shs$152.60 million Related Companies NUVB Stock Price Chart BCYC Stock Price Chart IMNM Stock Price Chart DNTH Stock Price Chart PHAR Stock Price Chart GHRS Stock Price Chart KALV Stock Price Chart VECT Stock Price Chart QURE Stock Price Chart ANAB Stock Price Chart Receive IKT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NYSE:IKT) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IKT Stock Free IKT Stock Alerts